ACXP - Acurx Pharmaceuticals Stock Is Plummeting After Biotech Publishes Phase 2 Results | Benzinga
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) shares are trading lower after the company released efficacy results from a Phase 2 trial.
The company, which had $9.1 million in cash and no debt in June, previously decided to terminate the Phase 2b vancomycin-controlled trial segment early. Aggregate blinded data showed a high observed clinical cure rate with no emerging safety concerns.
Acurx also decided that the clinical cure rate for ibezapolstat, to treat C. difficile Infection (CDI), was projected to be at least 90% pooled across the open-label Phase 2a and the blinded Phase 2b segments with no safety concerns noted.
Other factors, including the cost and the challenging enrollment ...